AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome

NNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Compound 530784: 4-Cyanobenzoic acid, 2-chlorophenyl ester

Chemical compound data from PubChem database. IUPAC Name: (2-chlorophenyl) 4-cyanobenzoate. Molecular Formula: C14H8ClNO2. Molecular Weight: 257.67. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Ohio 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
NNDSS - Table 1H.  Cholera to Coccidioidomycosis

NNDSS - Table 1H.  Cholera to Coccidioidomycosis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Data from California published in week 29 for years 2019 and 2020 were incomplete when originally published on July 24, 2020. On August 4, 2020, incomplete case counts were replaced with a "U" indicating case counts are not available for specified time period. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Palonosetron hydrochloride

Palonosetron Hydrochloride is a prescription injectable medication used to prevent nausea and vomiting caused by chemotherapy or surgery. It's administered intravenously by healthcare professionals. Manufactured by Teva Parenteral Medicines, Inc., under ANDA090713, it's available in strengths like 0.25 mg/5 mL. This information was generated using AI and is provided for informational and research purposes only.
San Francisco – SF Div: Drug-Related Emergency Department Visits, 2004-2011 - Suicide Attempts

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts in the San Francisco division of the San Francisco metropolitan area, covering 2004-2011.  Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.
Relatedness of baculovirus and

Background
          Current evidence suggests that lepidopteran baculoviruses may be divided into two phylogenetic groups based on their envelope fusion proteins. One group utilizes gp64, a low pH-dependent envelope fusion protein, whereas the other employs a protein family (e.g. LD130 in the Lymantria dispar nucleopolyhedrovirus) unrelated to gp64, but that is also low pH-dependent. Database searches with members of the LD130 protein family often record significant levels of homology to envelope proteins from a number of insect retrovirus-like transposable elements of the gypsy class. In this report, the significance of the homology between these two types of envelope proteins is analyzed.
        
        
          Results
          The significance of the alignment scores was evaluated using Z-scores that were calculated by comparing the observed alignment score to the distribution of scores obtained for alignments after one of the sequences was subjected to 100 random shuffles of its sequence. These analyses resulted in Z-scores of >9 for members of the LD130 family when compared to most gypsy envelope proteins. Furthermore, in addition to significant levels of sequence homology and the presence of predicted signal sequences and transmembrane domains, members of this family contain a possible a furin cleavage motif, a conserved motif downstream of this site, predicted coiled-coil domains, and a pattern of conserved cysteine residues.
        
        
          Conclusions
          These analyses provide a link between envelope proteins from a group of insect retrovirus-like elements and a baculovirus protein family that includes low-pH-dependent envelope fusion proteins. The ability of gypsy retroelements to transpose from insect into baculovirus genomes suggests a pathway for the exchange of this protein between these viral families.
Supporting Military Families

The Department of Defense is keenly aware of the needs of military families whose members are serving overseas. The presentation outlines the department’s prevention programs and how they are geared to provide support to active duty and reserve component members and their children, youth, and families. Among the resources mentioned are Military OneSource, the Military and Family Life Consultant Program, and MilitaryHOMEFRONT.

Presenters: Karen Morgan and Tib Campise from the Department of Defense Family Advocacy Program

View Webinar (WMV - 58 MB)

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526254: 1,2,6-Tribromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,6-tribromodibenzofuran. Molecular Formula: C12H5Br3O. Molecular Weight: 404.88. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401111-T1: [Translated] CLAMPING AND EXERCISE DEVICE

A restraint and exercise device (1,50,60,80, 101) is provided to treat acute or chronic mechanical pain, particularly lumbopelvic and/or leg pain, and to restore and/or increase range of motion in suitable users. The device is particularly useful during exercise. The device may contain a restraint, such as two straps(5,6), connected to a support structure (2). The straps (5, 6) help restrain a portion of a person' s body (30) such as the pelvic region (31 ). The portion of the person's body (30) may be restrained in a substantially pain-free position so as to reduce the pain that would otherwise be felt during exercise.
Compound 525442: Trimethylenebisethylsulfide

Chemical compound data from PubChem database. IUPAC Name: 1,3-bis(ethylsulfanyl)propane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401689-T1: [Translated] EMERGENCY RADIO, EMERGENCY LIGHTS AND EMERGENCY POWER SUPPLY

An emergency device (10) having a housing (12) with an illumination device (42,144), and a receiver (48), tuner and speakers (54) positioned within the housing. A power source is electrically coupled with the emergency device and is generally a conventional power cord (30). An outage circuit (100) is coupled with the power source. Upon sensing a power outage, the outage circuit, which is connected to the illuminating device (42,144), illuminates the illuminating device (42,144) or another auxiliary device.
Compound 528236: Benzo[b]thiophene, 4-nonyl

Chemical compound data from PubChem database. IUPAC Name: 4-nonyl-1-benzothiophene. Molecular Formula: C17H24S. Molecular Weight: 260.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: United States, 2014

This is a behavioral health report for the United States. The report utilizes data from the National Survey on Drug Use and Health (NSDUH), the Youth Risk Behavior Survey (YRBS), the Monitoring of the Future Survey (MtF) sponsored by the National Institute on Drug Abuse. The topics addressed in the report include youth substance use, youth mental health and treatment, adult mental health and treatment, substance use and substance use treatment.
Localities for 2012A

Physician Fee Schedule - March 2012 release. This file contains the revisions identified in the Middle Class Tax Relief and Job Creation Act of 2012 (MCTRJCA). Medicare payment rates under the Medicare Physician Fee Schedule (MPFS) are set according to statutory criteria. The following 2012 MPFS payment rates are reflective of the CY 2012 Medicare Physician Fee Schedule Final Rule, which was published in the Federal Register on November 28, 2011, and the CY 2012 Medicare Physician Fee Schedule Final Rule Correction Notice, which was published in the Federal Register on January 4, 2012. These payment rates are based on current law, including the Middle Class Tax Relief and Job Creation Act of 2012 (MCTRJCA), which provides for a zero percent update through December 31, 2012. The MCTRJCA extends several provisions of the Temporary Payroll Tax Cut Continuation Act of 2011 (TPTCCA). Please note that MCTRJCA does NOT extend add-on payments for mental health services and minimum payment for bone mass measurement (sections 307 and 309 of the TPTCCA, respectively). As such, effective March 1, 2012, the MPFS payment rates for these services have changed. 2012A: Medicare payment rates under the Medicare Physician Fee Schedule (MPFS) are set according to statutory criteria. The following 2012 MPFS payment rates are reflective of the CY 2012 Medicare Physician Fee Schedule Final Rule, which was published in the Federal Register on November 28, 2011, and the CY 2012 Medicare Physician Fee Schedule Final Rule Correction Notice that was put on display at the Office of the Federal Register on December 30, 2011. These payment rates are based on current law, including the Temporary Payroll Tax Cut Continuation Act of 2011, which provides for a zero percent update for the period of January 1, 2012 to February 29, 2012. The Centers for Medicare and Medicaid Services will work quickly to update MPFS payment rates in the event Congress passes legislation to prevent the negative update from going into effect on March 1, 2012. Please be on the alert for more information about the 2012 physician update as it becomes available.
The identity and distribution of neural cells expressing the mesodermal determinant

Background
          The spadetail (spt) gene of zebrafish is expressed in presomitic mesoderm and in neural cells previously suggested to be Rohon-Beard neurons. The mechanism(s) generating the apparently irregular rostrocaudal distribution of spt-expressing cells in the developing CNS is unknown.
        
        
          Results
          spt-expressing neural cells co-express huC, a marker of neurons. These cells also co-express the genes islet-1, -2 and -3 but not valentino. The islet-1 gene expression, irregular distribution and dorsolateral position of spt-expressing cells in the developing CNS are characteristic of dorsal longitudinal ascending (DoLA) interneurons. Shortly after their birth, these neurons extend processes rostrally into which spt mRNA is transported. At 24 hours post fertilisation(hpf), spt-expressing neurons occur most frequently at rostral levels caudal of the 5th-formed somite pair. There is no apparent bias in the number of spt-expressing cells on the left or right sides of embryos. Extended staining for spt-transcription reveals expression in the dorsocaudal cells of somites at the same dorsoventral level as the spt-expressing neurons. There is frequent juxtaposition of spt-expression in newly formed somites and in neurons. This suggests that both types of spt-expressing cell respond to a common positional cue or that neurons expressing spt are patterned irregularly by flanking somitic mesoderm.
        
        
          Conclusions
          spt-expressing cells in the developing CNS appear to be DoLA interneurons. The irregular distribution of these cells along the rostrocaudal axis of the spinal cord may be due to "inefficient" patterning of neural spt expression by a signal(s) from flanking, regularly distributed somites also expressing spt.
Minnesota (MN)

This report presents Minnesota\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Minnesota for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Centers for Disease Control (CDC) Data & Statistics by Topic

Includes information on the following topics:
Aging, Alcohol, Arthritis,Asthma, Autism (ASD), Birth Defects, Births, Blood Disorders,  Breastfeeding, Cancer, Chronic Diseases, Deaths, Diabetes, Disease Classification, Foodborne Illness, Genomics, Growth Charts, Healthy Water, Heart Disease, HIV/AIDS, Immunizations, Injuries & Violence, Life Expectancy, Lyme Disease, MRSA, Oral Health, Overweight & Obesity, Physical Inactivity, reproductive Health, Smoking & Tobacco, STDs, Vital Signs, Workplace
Inpatient, Emergency Department, and Outpatient Visits for Respiratory Illnesses

This dataset includes aggregated weekly data on the percent of emergency department visits and the percent of hospital inpatient admissions due to influenza-like illness (ILI), COVID-19, influenza, RSV, and acute respiratory illness. The Illinois Department of Public Health (IDPH) collects data for Emergency Department visits to all 185 acute care hospitals in Illinois. The data are submitted from IDPH to the CDC’s BioSense Platform for access and analysis by health departments via the ESSENCE system.

The CDC National Syndromic Surveillance Program (NSSP) utilizes diagnostic codes and clinical terms to create definitions for diagnosed COVID-19, influenza, RSV, and acute respiratory illness. For more information on diagnostic codes and clinical terms used, visit: https://www.cdc.gov/nssp/php/onboarding-resources/companion-guide-ed-data-respiratory-illness.html

The data is characterized by selected demographic groups including age group and race/ethnicity.

The dataset also includes percent of weekly outpatient visits due to ILI as reported by several outpatient clinics throughout Chicago that participate in CDC’s
Influenza-like Illness Surveillance Network (ILINet). 

For more information on ESSENCE, see https://www.dph.illinois.gov/data-statistics/syndromic-surveillance

For more information on ILINet, see https://www.cdc.gov/fluview/overview/index.html#cdc_generic_section_3-outpatient-illness-surveillance

All data are provisional and subject to change. Information is updated as additional details are received. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources.
Drug Abuse Warning Network (DAWN-2006)

<p>The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.<br />
DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.<br />
The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year.  Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.</p>
Compound 526217: 1,2-Dibromo-3,4,7,8-tetrachloro-dibenzo-p-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,2-dibromo-3,4,7,8-tetrachlorodibenzo-p-dioxin. Molecular Formula: C12H2Br2Cl4O2. Molecular Weight: 479.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.